UC Davis Offers Stroke-Prevention Alternative for Patients with Atrial Fibrillation


New device recommended for patients who can't tolerate blood thinners.

Cardiologists at UC Davis were the first in the Sacramento region to treat the major risk of stroke that comes with atrial fibrillation (AFib), the most common form of arrhythmia, with a new device that blocks blood clots from traveling from the heart to the head.

The tiny, flexible, metal-and-mesh shield known as the Watchman is placed using a catheter at the opening of the left atrial appendage — a small pouch in the upper chamber where blood can pool and clot when the heart beats out of sync.

Because 95 percent of strokes in AFib patients are caused by clots that travel from the left atrial appendage to the narrow vessels in the brain, nearly all patients with the condition are first treated with blood thinners. These medications, however, significantly increase the chances of bleeding disorders and require constant patient oversight.

“Treatments for regulating heart-rhythm problems that occur with AFib are constantly getting better,” said Jason Rogers, director of interventional cardiology at UC Davis Health System. “At the same time, stroke-prevention options beyond anticoagulants haven’t changed much for patients who can’t tolerate these medications.”

Carol Woody was one of those patients.

“When I was hospitalized for bleeding, my doctor and I knew we had to try something else,” Woody said.

The Manteca, Calif., retiree was first diagnosed with AFib seven years ago when she became too tired for even simple, everyday activities.

“The exhaustion was overwhelming,” she said. “There were days when it was really hard to get out of bed.”

While electrical cardioversion, or a low-voltage electric current, helped reset her heart rhythm, she was referred to Rogers, a specialist in catheter-based treatments for heart disease, to address her stroke risk.

Rogers and his team in the UC Davis Structural Heart Disease Clinic thought Woody was a good candidate for the new device, which was evaluated at UC Davis as part of a clinical trial. The study compared the safety and efficacy of the Watchman with a traditional blood-thinning medication and found that those with the implant had fewer bleeding complications and improved survival during five years of follow up. As a result, the device was approved in March 2015 by the FDA for patients with adverse reactions to blood thinners.

During a one-hour procedure, Rogers implanted the device in Woody’s heart using a small catheter that he threaded through her femoral vein, starting from her groin. He positioned it at the opening of the left atrial appendage where it will permanently stay, trapping clots where they are harmless.

Woody was in the hospital for one night and will see Rogers twice for follow-up exams. While she is still taking blood-clot medications, she will be weaned off of them within six months.

“I can’t wait for my time with blood thinners to be over,” she said.

Rogers is currently following numerous patients who have received the device. The biggest change has been in their quality of life, he said.

“They are ecstatic that there is something that can help prevent strokes, and that they don’t have to live constantly worried about the fear of bleeding problems,” Rogers said.

An innovative structural heart disease team at UC Davis, led by chief of cardiovascular medicine Reginald Low and cardiologist Jason Rogers, uses the latest minimally invasive and percutaneous procedures to treat problems with heart valves or tissue due to congenital defects or disease. More information is at www.ucdmc.ucdavis.edu/heart. To request a referral, call 1-800-4-UCDAVIS.

More stories about heart and vascular care at UC Davis:

UC Davis reaches a milestone in treating heart valve disease

UC Davis shows its commitment to heart health

New thoracic outlet syndrome clinic opens

Nerve regeneration therapy has potential to prevent arrhythmias, sudden cardiac death after heart attack

UC Davis launches stem cell study to reduce amputations from vascular disease

A new era in cardiovascular care

Related Videos
Video 6 - "Evaluating Safety of Novel LDL Management Mechanism"
Video 5 - "Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data"
Video 4 - "Innovations in Small Interfering RNA (siRNA) Therapy"
Video 3 - "Ongoing Lp(a) Trials and Clinical Approaches to Treatment"
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Payal Kohli, MD | Credit: Cherry Creek Heart
Matthew Nudy, MD | Credit: Penn State Health
Kelley Branch, MD, MSc | Credit: University of Washington Medicine
Stephanie Nahas, MD, MSEd | Credit: Jefferson Health
Kelley Branch, MD, MS | Credit: University of Washington Medicine
© 2024 MJH Life Sciences

All rights reserved.